Moderna, Inc.

Moderna is a leader in mRNA medicine, developing vaccine and therapeutic candidates across infectious disease, oncology, and rare disease. The company currently has three commercial products: Spikevax and mNEXSPIKE, which are COVID vaccines, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). mNEXSPIKE, launched commercially in the third quarter of 2025, is Moderna's leading product in the U.S. retail channel. In 2025, Moderna achieved total revenue of $1.9 billion, primarily from sales of its COVID vaccines. Beyond commercial products, Moderna is advancing a pipeline of development candidates. In January 2026, Moderna and Merck announced five-year data from a Phase 2b study of intismeran autogene (mRNA-4157), an mRNA-based individualized neoantigen therapy, in combination with Merck's pembrolizumab (KEYTRUDA®). This study demonstrated sustained improvement in recurrence-free survival in patients with high-risk melanoma (stage III/IV) following complete resection. Moderna is advancing intismeran with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types. In oncology, Moderna is also advancing mRNA-4359, a cancer antigen therapy. In infectious disease, regulatory filings are under review for its seasonal flu+COVID combination vaccine candidate (mRNA-1083) in Europe and Canada, and for its seasonal flu vaccine candidate (mRNA-1010) in the United States, Europe, Canada, and Australia.